BALA CYNWYD, Pa., Dec. 15, 2014 /PRNewswire/ -- Law office of
Brodsky & Smith, LLC announces that it is investigating
potential claims against the Board of Directors of Cubist
Pharmaceuticals, Inc. ("Cubist Pharmaceuticals" or the
"Company") (Nasdaq-CBST- News) for possible breaches of fiduciary
duty and other violations of state law in connection with the sale
of the Company to Merck & Co.
Click here to learn more about the investigation
http://brodsky-smith.com/865-cbst-cubist-pharmaceuticals-inc.html,
or call: 877-534-2590. There is no cost or obligation to you.
Under the terms of the transaction, Cubist Pharmaceuticals
shareholders will receive $102.00 in
cash for each share of Cubist Pharmaceuticals common stock they
own. The investigation concerns whether the Board of Cubist
Pharmaceuticals breached their fiduciary duties to stockholders by
failing to adequately shop the Company before agreeing to enter
into this transaction, and whether Merck & Co. is underpaying
for Cubist Pharmaceuticals shares.
If you own shares of Cubist Pharmaceuticals common stock and
wish to discuss the legal ramifications of the investigation, or
have any questions, you may e-mail or call the law office of
Brodsky & Smith, LLC who will, without obligation or cost to
you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire or Evan J. Smith, Esquire at Brodsky & Smith,
LLC, Two Bala Plaza, Suite 510, Bala Cynwyd, PA
19004, by e-mail at
investorrelations@brodsky-smith.com, by visiting
http://brodsky-smith.com/865-cbst-cubist-pharmaceuticals-inc.html,
or calling toll free 877-LEGAL-90.
Brodsky & Smith, LLC is a litigation law firm with extensive
expertise representing shareholders throughout the nation in
securities and case action lawsuits. The attorneys at Brodsky &
Smith have been appointed by numerous courts throughout the country
to serve as lead counsel in class actions and have successfully
recovered millions of dollars for our clients and shareholders.
Attorney advertising. Prior results do not guarantee a similar
outcome.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/shareholder-alert-brodsky--smith-llc-announces--investigation-of--the-board-of-directors-of-cubist-pharmaceuticals-inc-regarding-the-fairness-of-the-sale-of-the-company-300010080.html
SOURCE Brodsky & Smith, LLC